POM-V Prescription Required Companion Animal

Marbocyl SA 200 mg Powder and Solvent for Solution for Injection

Active ingredient: Marbofloxacin

Form

Injection

Species

Cats Dogs

Manufacturer

Vetoquinol SA

VMD MA No.

06462/3030

What it's used for

- in the treatment of lower or urinary tract infections due to coli and Proteus sp. In cats, Indicated: - in the treatment of infected wounds and subcutane...

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Marbofloxacin

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Marbocyl SA 200 mg Powder and Solvent for Solution for Injection — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 27 Mar 2026.

- in the treatment of lower or urinary tract infections due to
coli and Proteus sp.
In cats, Indicated:
- in the treatment of infected wounds and subcutaneous abscesses due
to Pasteurella multocida, Staphylococcus intermediusStaphylococcus
aureusStaphylococcus sp., Enterobacter sp. and Klebsiella sp.
Marbofloxacin is inactive against anaerobic bacteria.

technique withdraw 20ml from the vial of solvent and add rapidly to the
4yophilized powder. When reconstituted in this way, the solution will contain
10mg marbofloxacin per ml.
In dogs, the recommended doses and durations of treatment are:
For the treatment of infected wounds and subcutaneous abscesses – a
single subcutaneous or intravenous injection, at a dosage of 2mg/kg
(1ml/5kg), followed the next day by administration of Marbocyl Tablets daily
at a dosage of 2mg/kg for 6 days.
For the treatment of lower urinary tract infections – a single subcutaneous
or intravenous injection, at a dosage of 2mg/kg (1ml/5kg), followed the next
day by administration of Marbocyl Tablets daily at 2mg/kg for at least 10
days and up to 28 days.
In cats, the recommended doses and durations of treatment are:
For the treatment of infected wounds and subcutaneous abscesses – 2
mg/kg/day (0.2ml/kg/day), by subcutaneous or intravenous injection followed
by subcutaneous injections for a total of 3 to 5 days.

Marbofloxacin should not be used in dogs aged less than 12 months or less
than 18 months for exceptionally large breeds of dogs, such as Great Danes
or mastiffs with a longer growth period.
Do not use in cases of resistance to other fluoroquinolones (cross-
resistance).
Do not use in cases of hypersensitivity to the active substance, to any other
quinolones or to any of the excipients.

Cats and Dogs:
Very rare (<1 animal / 10,000
animals treated, including isolated
reports):
Neurological signs
; Seizure
;
Ataxia
; Mydriasis
; Muscle tremor
Hypersalivation ; emesis ; Injection
site reaction.
In severe cases, symptomatic treatment should be administered.
Reporting adverse events is important. It allows continuous safety
monitoring of a veterinary medicinal product. Reports should be sent,
preferably via a veterinarian, to either the marketing authorisation holder or
the national competent authority via the national reporting system. See the
package leaflet for respective contact details.

None

Special precautions for safe use in the target species:
Fluoroquinolones have been shown to induce erosion of articular cartilage in
juvenile dogs and care should be taken to dose accurately especially in young
animals.
Fluoroquinolones are also known for their potential neurological side
effects. Cautious use is recommended in dogs and cats diagnosed as
suffering from epilepsy.
Fluoroquinolones should be reserved for the treatment of clinical conditions
which have responded poorly or are expected to respond poorly to other
classes of antimicrobials. Use of the product should be based on susceptibility
testing of the bacteria isolated from the animal. If this is not possible, therapy
should be based on local (regional, farm level) epidemiological information
about susceptibility of the target bacteria. Use of the product deviating from
the instructions given in the SPC may increase the prevalence of bacteria
resistant to the fluoroquinolones and may reduce effectiveness of treatment
with other quinolones due to the potential for cross-resistance.
Official and local antimicrobial policies should be taken into account when
the product is used..
Special precautions to be taken by the person administering the
veterinary medicinal product to animals:
People with known hypersensitivity to (fluoro)quinolones should avoid using
this product.
In case of contact with skin or eyes, rinse with plenty of water.
Accidental self-injection can induce slight irritation.
In case of accidental self-injection, seek medical advice and show the
package leaflet or label to the physician.
Wash hands after use.
Special precautions for the protection of the environment:
Not applicable.

The dosage of theophylline must be reduced when used concurrently.

Before reconstitution:
Do not store above 25°C.
Protect from light.
After reconstitution:
Do not store above 25°C.
Protect from light.

Not Applicable.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.